Clinical Experience of the Use of CT-P13, a Biosimilar to Infliximab in Patients with Inflammatory Bowel Disease: A Case Series

Background CT-P13 is the first biosimilar monoclonal antibody to infliximab. However, the antibody was tested only in rheumatoid arthritis and ankylosing spondylitis, which demonstrated equivalence to the originator in efficacy, safety, and pharmacokinetic profile. Extrapolation of its efficacy and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Digestive diseases and sciences 2015-04, Vol.60 (4), p.951-956
Hauptverfasser:	Kang, Yun-Seong, Moon, Hyoung Ho, Lee, Seung Eun, Lim, Yun Jeong, Kang, Hyoun Woo
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antibodies, Monoclonal - therapeutic use Antigen-antibody reactions Arthritis Biochemistry Biological products Biosimilar Pharmaceuticals - therapeutic use Care and treatment Complications and side effects Female Gastroenterology Hepatology Humans Inflammatory Bowel Diseases - drug therapy Infliximab Male Medical records Medicine Medicine & Public Health Middle Aged Monoclonal antibodies Oncology Original Article Retrospective Studies Rheumatoid factor Transplant Surgery Ulcerative colitis Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!